periods can be found on pages 4 and 11, respectively.
-- Significant Increase In Cash Flow From Operations: Cash flow from
operations for 2007 increased by $88.7 million or 26.8%.
-- Sales for full year 2008 are expected to meet the Company's 7% organic
growth goal. A modest additional carryover benefit in Q1 2008 from the
Epichem acquisition is expected. Currency benefits could add another
3% to growth if currency exchange rates remain at December 31, 2007
-- Based on these sales and currency expectations, a modest margin
contribution from the Company's supply chain initiative and a higher
effective tax rate ranging from 30% to 32%, management estimates full
year 2008 diluted EPS in the range of $2.52 to $2.62, an increase of
7.7% to 12.0% over 2007.
Commenting on fourth quarter performance and expectations for the full year of 2008, President and CEO Jai Nagarkatti said: "We are very pleased to have posted record results again in 2007. Annual sales exceeded $2 billion for the first time in our Company's history. And our efforts to expand margins through Process Improvement activities combined with lower interest costs enabled us to grow our EPS more rapidly than sales, despite a higher effective tax rate. Key initiatives supporting our customer centric focus enabled us to deliver sales exceeding $500 million for the third successive quarter."
Nagarkatti continued, "Fourth quarter achievements for our five key
growth initiatives included:
-- Continuing to enhance our customer centric focus, which enabled us to
deliver another quarter of strong sales performance. Our Research
Specialties unit delivered exceptional sales growth for the sixth
successive quarter, Research Essentials achieved better than expected
growth for the third con
|SOURCE Sigma-Aldrich Corporation|
Copyright©2008 PR Newswire.
All rights reserved